EVH — Evolent Health Income Statement
0.000.00%
Last trade - 00:00
- $3.48bn
- $3.88bn
- $1.96bn
- 43
- 39
- 82
- 55
R2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 687 | 925 | 908 | 1,352 | 1,964 |
Cost of Revenue | |||||
Gross Profit | 174 | 228 | 250 | 317 | 460 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 996 | 1,239 | 926 | 1,359 | 2,056 |
Operating Profit | -309 | -315 | -17.8 | -6.55 | -92.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -330 | -331 | -29.8 | -62.1 | -202 |
Provision for Income Taxes | |||||
Net Income After Taxes | -307 | -328 | -30.3 | -18.7 | -113 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -302 | -334 | -37.6 | -19.2 | -113 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -302 | -334 | -37.6 | -19.2 | -142 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.96 | -1.72 | -0.449 | 0.044 | -0.665 |